Teva Pharmaceutical Industries (TEVA) free cash flow

Free cash flow · fiscal 2025
$1.15B

Teva Pharmaceutical Industries (TEVA) generated free cash flow of $1.15B in fiscal 2025 (the year ended December 31, 2025). That is 53.3% higher than the $749.00M of fiscal 2024. Figures as of 18 Nov 2026, 12:40 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$1.15B
Change on fiscal 2024
+53.3%
Growth, 5 years
+12.5% a year
Growth, 10 years
−13.3% a year
Highest on record
$4.77Bfiscal 2015
Lowest on record
$223.00Mfiscal 2019
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Teva Pharmaceutical Industries free cash flow, in more detail

Over the five fiscal years to 2025 free cash flow grew at a compound 12.5% a year; over ten years the rate was −13.3% a year. Across the 19 fiscal years on record (2007–2025), the highest was $4.77B in fiscal 2015 and the lowest $223.00M in fiscal 2019.

History · 19 fiscal years

Free cash flow by fiscal year

Teva Pharmaceutical Industries free cash flow, year by year

Teva Pharmaceutical Industries (TEVA) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$1.15B 53.3% up
2024$749.00M 11.0% down
2023$842.00M 19.2% down
2022$1.04B 341.5% up
2021$236.00M 63.0% down
2020$638.00M 186.1% up
2019$223.00M 87.6% down
2018$1.80B 32.9% up
2017$1.35B 54.8% down
2016$2.99B 37.3% down
2015$4.77B 13.6% up
2014$4.20B 90.3% up
2013$2.21B 36.4% down
2012$3.47B 12.6% up
2011$3.08B 10.1% down
2010$3.43B 29.1% up
2009$2.65B 4.1% up
2008$2.55B 100.6% up
2007$1.27B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

More on TEVA

Teva Pharmaceutical Industries, figure by figure

Teva Pharmaceutical Industries (TEVA) overview: price, valuation and scorecardAll health care companies by market value

Teva Pharmaceutical Industries free cash flow: questions and answers

What is Teva Pharmaceutical Industries's free cash flow?

Teva Pharmaceutical Industries (TEVA) generated free cash flow of $1.15B in fiscal 2025 (the year ended December 31, 2025). That is 53.3% higher than the $749.00M of fiscal 2024.

What is the growth rate of Teva Pharmaceutical Industries's free cash flow?

Over the five fiscal years to 2025 free cash flow grew at a compound 12.5% a year; over ten years the rate was −13.3% a year.

What are the highest and lowest free cash flow figures on record for Teva Pharmaceutical Industries?

Across the 19 fiscal years on record (2007–2025), the highest was $4.77B in fiscal 2015 and the lowest $223.00M in fiscal 2019.

How is Teva Pharmaceutical Industries's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Teva Pharmaceutical Industries it is on record here for 19 fiscal years, 2007 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Teva Pharmaceutical Industries (TEVA) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/TEVA/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.